Provides cutting edge solutions to improve physician awareness in minimizing Adverse Drug Reactions.
Through innovative technology, Selecta Labs provides cutting edge solutions to improve physician awareness in minimizing Adverse Drug Reactions (ADRs), identifying narcotic diversion, and providing personalized prescribing and patient care. At Selecta Labs, we strive to bring you around-the-clock innovations in laboratory testing; from detailed, genetic and DNA studies, to easy to read toxicology reports and drug screenings. Using pharmacogenetics, physicians can customize treatment plans that minimize Adverse Drug Reactions (ADRs).
Many medications that are currently available are “one size fits all,” but they don’t work the same way for everyone. It can be difficult to predict who will benefit from a medication, who will not respond at all, and who will experience negative side effects called Adverse Drug Reactions (ADRs). Even with the appropriate prescription, patient’s genetics will impact how a patient metabolizes and responds to prescription drugs.
More than 8.6 million Adverse Drug Reactions (ADRs) occur every year ¬— 2.2 million of them are severe. Admittedly, ADRs are the fourth leading cause of death nationwide, after heart disease, cancer and stroke. ADRs place a huge financial burden on the healthcare system. Selecta Labs Pharmacogenetics Testing determines how a patient will metabolize and respond to a prescription drug.
Now, clinicians have a clear, actionable guide addressing the complexities of drug interaction and the impact of individual genetics on drug metabolization. This guide provides personalized prescribing care which reduces ADRs, ultimately improving patient results and lowering healthcare costs.
We target a wide variety of specialties, from pain management, to mental health to cardiology. Each specialty has its own particular test, demands, procedures, and protocols.
Treating and preventing heart disease is not an easy task due to each individual metabolic system. Today, health care providers have written millions of prescriptions for cardiovascular disease but finding the correct drug and dose is difficult. There are three enzymes called CYP2D6, CYP2C9 and CYP2C19 that play an important factor in metabolizing all medications as well as heart disease medications.
Selecta Labs offers health care providers the tools to personalize prescribing and lower the possibilities of Adverse Drug Reactions (ADRs). Our unique comprehensive cardiac panels empowers a physician with crucial information that can determine risk factors and can therefore select the right drug and dose for each individual patient.
Pharmacogenetics research will clarify psychiatry on mental disorders, reasons for treatment failure, and Adverse Drug Reactions (ADRs). Variations of Cytochrome P450 (CYP) enzymes are common and can influence and determine the effectiveness of drugs. Pharmacogenetics testing will eliminate ADR’s and may help improve adherence.
It is well documented that 30 to 50 percent of psychiatric patients respond inadequately to intensive treatment, regardless of the initial choice of standard psychiatric medication. Our panels will help identify patients’ metabolic profiles and give psychiatrist the knowledge they need when prescribing for psychiatric patients.
Our genetic tests, created precisely for orthopedic medicine, offer clinically actionable, predictive information to identify inherited coagulation pathway deficits. These deficits increase the risk of thrombosis. Choosing Pharmacogenetics research will help determine appropriate anti-coagulation therapy and target effective pain control medications to minimize post-operative pain.
The pre-operative genetic testing panel will identify which patients are at risk for excessive bleeding and thrombotic events. It will also assist in determining low or non-responders to pain control medications for post operative patients.
Selecta Labs offers a Pharmacogenetics metabolic testing panel providing pain management specialist dependable information to improve the lives of pain sufferers. Physicians can now provide personalized prescribing, patient care and reduce the chances of Adverse Drug Reactions (ADRs) by identifying patients’ drug metabolizing phenotypes.
Like all diagnostic tests, CYP2D6 genotype is one of various pieces of information that clinicians should consider in caring for their patients. To help predict potential variability, physicians are progressively depending on Pharmacogenetics testing to provide them with vital knowledge about the genetics of their patients.
What is Verifi® by Selecta Labs?
Verifi® by Selecta Labs is a simple blood test that screens for the most common chromosomal abnormalities that can affect your baby’s future health. A sample can be drawn in your doctor’s office as early as the 10th week of pregnancy, and it may help you avoid more invasive procedures, such as amniocentesis or chorionic villus sampling (CVS), which are not without risks to you and your baby. verifi® by Selecta Labs is available for both singleton and twin pregnancies.* Test results are usually reported back to your healthcare provider within approximately 1 week’s time.
How does the test work?
A sample of your blood is drawn and the genetic material (DNA) from you and your baby is tested. verifi® by Selecta Labs takes a deeper approach to the science, using an advanced technology called “Massively Parallel Sequencing” to analyze millions of DNA fragments per sample and accurately count the number of chromosomes present. It then uses a special SAFeR™ calculation method to determine if there are too many or too few copies of these chromosomes in your baby.